Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks

Paul A. Gurbel, Elisabeth Mahla, Udaya S. Tantry

Research output: Contribution to journalArticle

Abstract

The pivotal role of platelet activation and reactivity during atherothrombotic event occurrence associated with acute coronary syndromes (ACS) or percutaneous coronary interventions (PCI) is well established. Numerous translational research studies have established a threshold level of platelet reactivity during dual antiplatelet therapy above which a higher risk for ischaemic event occurrence has been observed. The clinical validity of these threshold values in reducing ischemic event occurrence with modified P2Y 12 receptor therapy is currently under investigation in large-scale clinical trials. The association between on-treatment platelet reactivity measured by an ex vivo assay and the occurrence of bleeding events is less established. Currently, there is limited evidence of an association between platelet inhibition and coronary artery bypass grafting (CABG)- related bleeding in patients on clopidogrel therapy indicating that preoperative platelet function monitoring may guide both the timing of elective CABG and the administration of blood products in patients needing surgery. However, in the absence of a large-scale prospective clinical trial, routine platelet function monitoring and modification of timing of surgery based on platelet function monitoring are currently not recommended.

Original languageEnglish (US)
Pages (from-to)248-252
Number of pages5
JournalThrombosis and Haemostasis
Volume106
Issue number2
DOIs
StatePublished - 2011

Fingerprint

Blood Platelets
Hemorrhage
clopidogrel
Coronary Artery Bypass
Clinical Trials
Translational Medical Research
Platelet Activation
Percutaneous Coronary Intervention
Therapeutics
Acute Coronary Syndrome

Keywords

  • Antiplatelet drugs
  • Atherothrombosis
  • Platelet pharmacology

ASJC Scopus subject areas

  • Hematology

Cite this

Peri-operative platelet function testing : The potential for reducing ischaemic and bleeding risks. / Gurbel, Paul A.; Mahla, Elisabeth; Tantry, Udaya S.

In: Thrombosis and Haemostasis, Vol. 106, No. 2, 2011, p. 248-252.

Research output: Contribution to journalArticle

Gurbel, Paul A. ; Mahla, Elisabeth ; Tantry, Udaya S. / Peri-operative platelet function testing : The potential for reducing ischaemic and bleeding risks. In: Thrombosis and Haemostasis. 2011 ; Vol. 106, No. 2. pp. 248-252.
@article{472f1fcdbf9d42f7b0253f5b074a6b1d,
title = "Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks",
abstract = "The pivotal role of platelet activation and reactivity during atherothrombotic event occurrence associated with acute coronary syndromes (ACS) or percutaneous coronary interventions (PCI) is well established. Numerous translational research studies have established a threshold level of platelet reactivity during dual antiplatelet therapy above which a higher risk for ischaemic event occurrence has been observed. The clinical validity of these threshold values in reducing ischemic event occurrence with modified P2Y 12 receptor therapy is currently under investigation in large-scale clinical trials. The association between on-treatment platelet reactivity measured by an ex vivo assay and the occurrence of bleeding events is less established. Currently, there is limited evidence of an association between platelet inhibition and coronary artery bypass grafting (CABG)- related bleeding in patients on clopidogrel therapy indicating that preoperative platelet function monitoring may guide both the timing of elective CABG and the administration of blood products in patients needing surgery. However, in the absence of a large-scale prospective clinical trial, routine platelet function monitoring and modification of timing of surgery based on platelet function monitoring are currently not recommended.",
keywords = "Antiplatelet drugs, Atherothrombosis, Platelet pharmacology",
author = "Gurbel, {Paul A.} and Elisabeth Mahla and Tantry, {Udaya S.}",
year = "2011",
doi = "10.1160/TH11-02-0063",
language = "English (US)",
volume = "106",
pages = "248--252",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Peri-operative platelet function testing

T2 - The potential for reducing ischaemic and bleeding risks

AU - Gurbel, Paul A.

AU - Mahla, Elisabeth

AU - Tantry, Udaya S.

PY - 2011

Y1 - 2011

N2 - The pivotal role of platelet activation and reactivity during atherothrombotic event occurrence associated with acute coronary syndromes (ACS) or percutaneous coronary interventions (PCI) is well established. Numerous translational research studies have established a threshold level of platelet reactivity during dual antiplatelet therapy above which a higher risk for ischaemic event occurrence has been observed. The clinical validity of these threshold values in reducing ischemic event occurrence with modified P2Y 12 receptor therapy is currently under investigation in large-scale clinical trials. The association between on-treatment platelet reactivity measured by an ex vivo assay and the occurrence of bleeding events is less established. Currently, there is limited evidence of an association between platelet inhibition and coronary artery bypass grafting (CABG)- related bleeding in patients on clopidogrel therapy indicating that preoperative platelet function monitoring may guide both the timing of elective CABG and the administration of blood products in patients needing surgery. However, in the absence of a large-scale prospective clinical trial, routine platelet function monitoring and modification of timing of surgery based on platelet function monitoring are currently not recommended.

AB - The pivotal role of platelet activation and reactivity during atherothrombotic event occurrence associated with acute coronary syndromes (ACS) or percutaneous coronary interventions (PCI) is well established. Numerous translational research studies have established a threshold level of platelet reactivity during dual antiplatelet therapy above which a higher risk for ischaemic event occurrence has been observed. The clinical validity of these threshold values in reducing ischemic event occurrence with modified P2Y 12 receptor therapy is currently under investigation in large-scale clinical trials. The association between on-treatment platelet reactivity measured by an ex vivo assay and the occurrence of bleeding events is less established. Currently, there is limited evidence of an association between platelet inhibition and coronary artery bypass grafting (CABG)- related bleeding in patients on clopidogrel therapy indicating that preoperative platelet function monitoring may guide both the timing of elective CABG and the administration of blood products in patients needing surgery. However, in the absence of a large-scale prospective clinical trial, routine platelet function monitoring and modification of timing of surgery based on platelet function monitoring are currently not recommended.

KW - Antiplatelet drugs

KW - Atherothrombosis

KW - Platelet pharmacology

UR - http://www.scopus.com/inward/record.url?scp=79961092373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961092373&partnerID=8YFLogxK

U2 - 10.1160/TH11-02-0063

DO - 10.1160/TH11-02-0063

M3 - Article

C2 - 21505715

AN - SCOPUS:79961092373

VL - 106

SP - 248

EP - 252

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -